Вміст фібронектину у сироватці крові хворих на цукровий діабет 2-го типу та ожиріння

Л. А. Могильницька

doi:10.24026/1818-1384.4(41).2012.86113

Автор(и)

Л. А. Могильницька Хмельницька обласна лікаря, ендокринологічне відділення, Україна

DOI:

https://doi.org/10.24026/1818-1384.4(41).2012.86113

Ключові слова:

fibronectin, endothelial dysfunction, type 2 diabetes mellitus, obesity

Анотація

Macro- and microvascular disease is the main cause of disability and death in diabetes. Endothelial dysfunction is considered an early and important step in the development of arterial disease. Circulating cellular fibronectin may be another useful marker of endothelial activation. The aim of study was to investigate serum level of fibronectin in patients with type 2 diabetes with different body mass and obesity. We found an increase of serum level of fibronectin in obese and non-obese diabetic patients and non-diabetic patients with obesity. Revealed changes may be a marker of endothelial dysfunction in diabetes and obesity.

Біографія автора

Л. А. Могильницька, Хмельницька обласна лікаря, ендокринологічне відділення

L. Mogylnytska

Посилання

Лысенко В. А., Маньковский Б. Н. Содержание инсулина в плазме крови и чувствительность к нему тканей у больных с впервые выявленным диабетом 2 типа // Врачебное дело. – 2000. – №6. – С. 46-49.

Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome — a new worldwide definition // Lancet. – 2011. – Vol. 366. – P. 1059-1062. https://doi.org/10.1016/s0140-6736(05)67402-8

Andresen J.L., Rasmussen L., Ledet T. Diabetic macroangiopathy and atherosclerosis// Diabetes. – 2006. – Vol. 45, suppl. 3. – P. 91-94. https://doi.org/10.2337/diab.45.3.s91

Bauters C., Marotte F., Hamon M. et al. Accumulation of fetal fibronectin mRNAs after balloon denudation of rabbit arteries // Circulation – 2005. – Vol. 92. – P. 904-911. https://doi.org/10.1161/01.cir.92.4.904

Caballero A.E., Arora S., Saouaf R. at al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes // Diabetes. – 2010. – Vol. 48. – P. 1856-1862. https://doi.org/10.2337/diabetes.48.9.1856

Fijnheer R., Frijns C.J., Korteweg J. et al. The origin of P-selectin as a circulating plasma protein // Thromb. Haemost. – 2007. – Vol. 77. – P. 1081-1085.

Friedman S.A., de Groot C., Taylor R., Golditch B., Roberts J.M. Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation // Am. J. Obstet. Gynecol. – 2010. – Vol. 170. – P. 838-841. https://doi.org/10.1016/s0002-9378(94)70295-0

Hynes R.O. Fibronectins // Sci. Am. – 2006. – Vol. 254. – P. 42-51. https://doi.org/10.1038/scientificamerican0686-42

Hynes R.O. Molecular biology of fibronectin // Ann. Rev. Cell. Biol. – 2005. – Vol. 1. – P. 67-90. https://doi.org/10.1146/annurev.cb.01.110185.000435

Kanters S.D., Banga J.D., Algra A., at al. Plasma Levels of Cellular Fibronectin in Diabetes // Diabetes Care. – 2011. – Vol. 24. – P. 323-327. https://doi.org/10.2337/diacare.24.2.323

Kornblihtt A.R., Pesce C.G., Alonso C.R. et al. The fibronectin gene as a model for splicing and transcription studies // FASEB J. – 2011. – Vol. 10. – P. 248-257.

Peters J.H., Sporn L.A., Ginsberg M.H., Wagner D.D. Human endothelial cells synthesize, process, and secrete fibronection molecules bearing an alternatively spliced type II homology (ED1) // Blood. – 2010. – Vol. 75. – P. 1801-1808.

Peters J.H., Maunder R.J., Woolf A.D., Cochrane C.G., Ginsberg M.H. Elevated plasma levels of ED1 ("cellular") fibronectin in patients with vascular injury // J. Lab. Clin. Med. – 2007. – Vol. 113. – P. 586-597.

Peters D.M.P., Mosher D.F. Localization of cell surface sites involved in fibronectin fibrillogenesis // J. Cell. Biol. – 2006. – Vol. 104. – P. 121-130. https://doi.org/10.1083/jcb.104.1.121

Spirin K.S., Saghizadeh M., Lewin S.L. et al. Basement membrane and growth factor gene expression in normal and diabetic human retinas// Curr. Eye. Res. – 2007. – Vol. 18. – P. 490-499. https://doi.org/10.1076/ceyr.18.6.490.5267

Van der Plas R.M., Schiphorst M.E., Huizinga E.G. et al. Von Willebrand factor proteolysis is deficient in classis, but not in bone marrow transplantationassociated, thrombotic thrombocytopenic purpura // Blood. – 2007. – Vol. 93. – P. 3798-3802.

Voskuyl A.E., Emeis J.J., Hazes J.M.W. et al. Levels of circulating cellular fibronectin are increased in patients with rheumatoid vasculitis // Clin. Exp. Rheumatol. – 2007. – Vol. 16. – P. 429-434.

Wang A., Cohen D.S., Palmer E., Sheppard D. Polarized regulation of fibronectin secretion and alternative splicing by transforming growth factor // J. Biol. Chem. – 2011. – Vol. 266. – P. 15598-15601.

Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T. Impaired nitric oxide-mediated vasodilatation in patients with non-insulin-dependent diabetes mellitus // J. Am. Coll. Cardiol. – 2006. – Vol. 27. – P. 567-574. https://doi.org/10.1016/0735-1097(95)00522-6

Yamada K., Kennedy D.W. Fibroblast cellular and plasma fibronectin are similar but not identical // J. Cell. Biol. – 2007. – Vol. 80. – P. 492-498. https://doi.org/10.1083/jcb.80.2.492